The current valuation of the Insomnia Market, reflected in its substantial Insomnia Market Size in billions of dollars, only represents the revenues generated from diagnosed cases and treated patients. A deeper analysis suggests that the true market potential is significantly larger, constrained by a vast, untapped pool of undiagnosed and untreated individuals worldwide. Current estimates indicate that a large percentage of adults experience symptoms of insomnia, but only a fraction seek and receive a formal diagnosis. This disparity is driven by factors such as lack of public awareness, reluctance to seek treatment due to stigma, and limited access to specialized sleep clinics, particularly in developing economies. Consequently, the market size is expected to expand dramatically as public health campaigns and technological advancements narrow this treatment gap.

The future expansion of the market size will be fueled by two main engines. Firstly, the increased prevalence and aging global population will naturally inflate the patient pool requiring intervention. Secondly, the market is expanding its definition of "treatment" to include easily accessible over-the-counter (OTC) sleep aids, herbal supplements, and consumer-grade sleep-tracking technology. While these consumer solutions may not address clinical-grade insomnia, their increasing sales contribute to the overall market valuation. Most critically, the deployment of scalable digital therapeutics (DTx) for Cognitive Behavioral Therapy for Insomnia (CBT-I) has a profound impact. By offering a convenient, affordable, and evidence-based option, DTx bypasses many traditional barriers to care, rapidly converting previously untreated sufferers into active market participants. As healthcare systems embrace screening and earlier intervention, the measured market size is poised for substantial upward revision throughout the forecast period.